{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:28:34Z","timestamp":1791077314573,"version":"4.1.0"},"reference-count":40,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"abstract":"<jats:p>Objective. The hemolytic uremic syndrome (HUS) consists of hemolytic anemia, thrombocytopenia, and renal failure. HUS is often precipitated by gastrointestinal infection with Shiga toxin\u2013producing Escherichia coli and is characterized by a variety of prothrombotic host abnormalities. In much of the world, E coli O157:H7 is the major cause of HUS. HUS can be categorized as either oligoanuric (which probably signifies acute tubular necrosis) or nonoligoanuric. Children with oligoanuric renal failure during HUS generally require dialysis, have more complicated courses, and are probably at increased risk for chronic sequelae than are children who experience nonoligoanuric HUS. Oligoanuric HUS should be avoided, if possible. The presentation to medical care of a child with definite or possible E coli O157:H7 infections but before HUS ensues affords a potential opportunity to ameliorate the course of the subsequent renal failure. However, it is not known whether events that occur early in E coli O157:H7 infections, particularly measures to expand circulating volume, affect the likelihood of experiencing oligoanuric HUS if renal failure develops. We attempted to assess whether pre-HUS interventions and events, especially the volume and sodium content of intravenous fluids administered early in illness, affect the risk for developing oligoanuric HUS after E coli O157:H7 infections.<\/jats:p><jats:p>Methods. We performed a prospective cohort study of 29 children with HUS that was confirmed microbiologically to be caused by E coli O157:H7. Infected children were enrolled when they presented with acute bloody diarrhea or as contacts of patients who were known to be infected with E coli O157:H7, or if they had culture-confirmed infection, or if they presented with HUS. HUS was defined as hemolytic anemia (hematocrit &amp;lt;30%, with fragmented erythrocytes on peripheral-blood smear), thrombocytopenia (platelet count of &amp;lt;150000\/mm3), and renal insufficiency (serum creatinine concentration that exceeded the upper limit of normal for age). A wide range of pre-HUS variables, including demographic factors, clinical history, medications given, initial laboratory values, and volume and content of parenteral fluid administered, were recorded and entered into analysis. Estimates of odds ratios were adjusted for possible confounding effects using logistic regression analysis. Twenty-nine children who were &amp;lt;10 years old, had HUS confirmed to be caused by E coli O157:H7, and were hospitalized at the Children's Hospital and Regional Medical Center, Seattle, were studied. The main outcome measured was development of oligoanuric renal failure. Oligoanuria was defined as a urine output &amp;lt;0.5 mL\/kg per hour for at least 24 consecutive hours.<\/jats:p><jats:p>Results. As a group, the children with oligoanuric renal failure presented to medical attention and were evaluated with laboratory testing later than the children with nonoligoanuric renal failure. On initial assessments, the children with oligoanuric outcomes had higher white blood cell counts, lower platelet counts and hematocrits, and higher creatinine concentrations than the children with nonoligoanuric outcomes, but these determinations probably reflect later points of these initial determinations, often when HUS was already developing. Stool cultures were obtained (medians of 3 vs 2 days, respectively) and positive (medians of 7 vs 4 days, respectively) at later points in illness in the children in the oligoanuric than in the nonoligoanuric group. Intravenous volume expansion began later in illness in the children who subsequently developed oligoanuric renal failure than in those whose renal failure was nonoligoanuric (medians: 4.5 vs 3.0 days, respectively). Moreover, the 13 patients with nonoligoanuric renal failure received more intravenous fluid and sodium before HUS developed (1.7- and 2.5-fold differences, respectively, between medians) than the 16 patients with oligoanuric renal failure. These differences were even greater when the first 4 days of illness were examined, with 17.1- and 21.8-fold differences, respectively, between medians. In a multivariate analysis adjusted for age, gender, antibiotic use, and free water volume administered intravenously to these children during the first 4 days of illness, the amount of sodium infused remained associated with protection against developing oligoanuric HUS. Dialysis was used in each of the children with oligoanuric renal failure and in none of the children with nonoligoanuric renal failure. The median length of stay in hospital after the diagnosis of HUS was 12 days in the oligoanuric group and 6 days in the nonoligoanuric group.<\/jats:p><jats:p>Conclusions. Early recognition of and parenteral volume expansion during E coli O157:H7 infections, well before HUS develops, is associated with attenuated renal injury failure. Parenteral hydration in children who are possibly infected with E coli O157:H7, at the time of presentation with bloody diarrhea and in advance of culture results, is a practice that can accelerate the start of volume expansion during the important pre-HUS interval. Rapid assessment of stools for E coli O157:H7 by microbiologists and reporting of presumptive positives immediately can alert practitioners that patients are at risk for developing HUS and can prompt volume expansion in children who are not already being so treated. Our data also suggest that isotonic intravenous solutions might be superior to hypotonic fluids for use as maintenance fluids. Children who are infected with E coli O157:H7 and are given intravenous volume expansion need careful monitoring. This monitoring should be even more assiduous as HUS evolves.<\/jats:p>","DOI":"10.1542\/peds.2004-2236","type":"journal-article","created":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T17:19:46Z","timestamp":1117646386000},"page":"e673-e680","source":"Crossref","is-referenced-by-count":189,"title":["Relative Nephroprotection During<i>Escherichia coli<\/i>O157:H7 Infections: Association With Intravenous Volume Expansion"],"prefix":"10.1542","volume":"115","author":[{"given":"Julie A.","family":"Ake","sequence":"first","affiliation":[{"name":"Department of Medicine, Madigan Army Medical Center, Tacoma, Washington"},{"name":"Children\u2019s Hospital and Regional Medical Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdjan","family":"Jelacic","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia A.","family":"Ciol","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital and Regional Medical Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L.","family":"Watkins","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital and Regional Medical Center, Seattle, Washington"},{"name":"Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen F.","family":"Murray","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital and Regional Medical Center, Seattle, Washington"},{"name":"Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis L.","family":"Christie","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital and Regional Medical Center, Seattle, Washington"},{"name":"Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen J.","family":"Klein","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital and Regional Medical Center, Seattle, Washington"},{"name":"Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip I.","family":"Tarr","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital and Regional Medical Center, Seattle, Washington"},{"name":"Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2005,6,1]]},"reference":[{"key":"2021120819223396300_R1","doi-asserted-by":"crossref","unstructured":"Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med.\u20082000;342:1930\u20131936","DOI":"10.1056\/NEJM200006293422601"},{"key":"2021120819223396300_R2","doi-asserted-by":"crossref","unstructured":"Tarr PI, Neill MA, Clausen CR, et al. Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J Infect Dis.\u20081990;162:553\u2013556","DOI":"10.1093\/infdis\/162.2.553"},{"key":"2021120819223396300_R3","doi-asserted-by":"crossref","unstructured":"Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities associated with Escherichia coli O157:H7 infections. N Engl J Med.\u20082002;346:23\u201332","DOI":"10.1056\/NEJMoa011033"},{"key":"2021120819223396300_R4","doi-asserted-by":"crossref","unstructured":"Bell BP, Griffin PM, Lozano P, et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics.\u20081997;100(1). Available at: www.pediatrics.org\/cgi\/content\/full\/100\/1\/e12","DOI":"10.1542\/peds.100.1.e12"},{"key":"2021120819223396300_R5","doi-asserted-by":"crossref","unstructured":"Ostroff SM, Kobayashi JM, Lewis JH. Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA.\u20081989;262:355\u2013359","DOI":"10.1001\/jama.262.3.355"},{"key":"2021120819223396300_R6","doi-asserted-by":"crossref","unstructured":"Gianantonio CA, Vitacco M, Mendilaharzu F, et al. The hemolytic-uremic syndrome. Renal status of 76 patients at long-term follow-up. J Pediatr.\u20081968;72:757\u2013765","DOI":"10.1016\/S0022-3476(68)80427-5"},{"key":"2021120819223396300_R7","doi-asserted-by":"crossref","unstructured":"Gianantonio CA, Vitacco M, Mendilaharzu F, et al. The hemolytic-uremic syndrome. Nephron.\u20081973;11:174\u2013192","DOI":"10.1159\/000180229"},{"key":"2021120819223396300_R8","doi-asserted-by":"crossref","unstructured":"Dolislager D, Tune B. The hemolytic-uremic syndrome: spectrum of severity and significance of prodrome. Am J Dis Child.\u20081978;132:55\u201358","DOI":"10.1001\/archpedi.1978.02120260057014"},{"key":"2021120819223396300_R9","doi-asserted-by":"crossref","unstructured":"de Jong M, Monnens L. Haemolytic-uraemic syndrome: a 10-year follow-up study of 73 patients. Nephrol Dial Transplant.\u20081988;3:379\u2013382","DOI":"10.1093\/oxfordjournals.ndt.a091684"},{"key":"2021120819223396300_R10","unstructured":"Robson WL, Fick GH, Wilson PC. Prognostic factors in typical postdiarrhea hemolytic-uremic syndrome. Child Nephrol Urol.\u20081988\u20131989;9:203\u2013207"},{"key":"2021120819223396300_R11","doi-asserted-by":"crossref","unstructured":"Siegler RL, Milligan MK, Burningham TH, et al. Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. J Pediatr.\u20081991;118:195\u2013200","DOI":"10.1016\/S0022-3476(05)80482-2"},{"key":"2021120819223396300_R12","doi-asserted-by":"crossref","unstructured":"Robson WL, Leung AK, Brant R. Relationship of the recovery in the glomerular filtration rate to the duration of anuria in diarrhea-associated hemolytic uremic syndrome. Am J Nephrol.\u20081993;13:194\u2013197","DOI":"10.1159\/000168617"},{"key":"2021120819223396300_R13","doi-asserted-by":"crossref","unstructured":"Tonshoff B, Sammet A, Sanden I, et al. Outcome and prognostic determinants in the hemolytic uremic syndrome of children. Nephron.\u20081994;68:63\u201370","DOI":"10.1159\/000188221"},{"key":"2021120819223396300_R14","doi-asserted-by":"crossref","unstructured":"Spizzirri FD, Rahman RC, Bibiloni N, et al. Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol.\u20081997;11:156\u2013160","DOI":"10.1007\/s004670050248"},{"key":"2021120819223396300_R15","doi-asserted-by":"crossref","unstructured":"Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA.\u20082003;290:1360\u20131370","DOI":"10.1001\/jama.290.10.1360"},{"key":"2021120819223396300_R16","doi-asserted-by":"crossref","unstructured":"Smith JM, Jones F, Ciol MA, et al. Platelet-activating factor and Escherichia coli O157:H7 infections. Pediatr Nephrol.\u20082002;17:1047\u20131052","DOI":"10.1007\/s00467-002-0970-7"},{"key":"2021120819223396300_R17","doi-asserted-by":"crossref","unstructured":"Tsai HM, Chandler WL, Sarode R, et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res.\u20082001;49:653\u2013659","DOI":"10.1203\/00006450-200105000-00008"},{"key":"2021120819223396300_R18","doi-asserted-by":"crossref","unstructured":"Lockitch G, Halstead AC, Albersheim S, et al. Age- and sex-specific pediatric reference intervals for biochemistry analytes as measured with the Ektachem-700 analyzer. Clin Chem.\u20081988;34:1622\u20131625","DOI":"10.1093\/clinchem\/34.8.1622"},{"key":"2021120819223396300_R19","doi-asserted-by":"crossref","unstructured":"Flancbaum L, Choban PS, Dasta JF. Quantitative effects of low-dose dopamine on urine output in oliguric surgical intensive care unit patients. Crit Care Med.\u20081994;22:61\u201368","DOI":"10.1097\/00003246-199401000-00014"},{"key":"2021120819223396300_R20","doi-asserted-by":"crossref","unstructured":"Tarr PI, Neill MA. Escherichia coli O157:H7. Gastroenterol Clin North Am.30:735\u2013751, 2001","DOI":"10.1016\/S0889-8553(05)70208-9"},{"key":"2021120819223396300_R21","doi-asserted-by":"crossref","unstructured":"Mosteller RD. Simplified calculation of body-surface area. N Engl J Med.\u20081987;317:1098","DOI":"10.1056\/NEJM198710223171717"},{"key":"2021120819223396300_R22","unstructured":"Sica DA, Schoolwerth AC. Renal handling of organic anions and cations and renal excretion of uric acid. In: Brenner BM, ed. Brenner and Rector's The Kidney. 5th ed. Philadelphia, PA: W.B. Saunders Company; 1996:607\u2013626"},{"key":"2021120819223396300_R23","unstructured":"O'Regan S, Rousseau E. Hemolytic uremic syndrome: urate nephropathy superimposed on an acute glomerulopathy? An hypothesis. Clin Nephrol.\u20081988;30:207\u2013210"},{"key":"2021120819223396300_R24","doi-asserted-by":"crossref","unstructured":"Kaplan BS, Thomson PD. Hyperuricemia in the hemolytic-uremic syndrome. Am J Dis Child.\u20081976;130:854\u2013856","DOI":"10.1001\/archpedi.1976.02120090064011"},{"key":"2021120819223396300_R25","unstructured":"Dubrow A, Flamenbaum W. Acute renal failure associated with myoglobinuria and hemoglobinuria. In: Flamenbaum W, Hamburger RJ, eds. Nephrology: An Approach to the Patient With Renal Disease. Philadelphia, PA: Lippincott; 1982:279\u2013293"},{"key":"2021120819223396300_R26","doi-asserted-by":"crossref","unstructured":"Hughes AK, Stricklett PK, Schmid D, et al. Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells. Kidney Int.\u20082000;57:2350\u20132359","DOI":"10.1046\/j.1523-1755.2000.00095.x"},{"key":"2021120819223396300_R27","doi-asserted-by":"crossref","unstructured":"Ramegowda B, Tesh VL. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect Immun.\u20081996;64:1173\u20131180","DOI":"10.1128\/iai.64.4.1173-1180.1996"},{"key":"2021120819223396300_R28","doi-asserted-by":"crossref","unstructured":"Mayer J, Doubek M, Doubek J, et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis.\u20082002;186:379\u2013388","DOI":"10.1086\/341662"},{"key":"2021120819223396300_R29","doi-asserted-by":"crossref","unstructured":"Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med.\u20082002;162:329\u2013336","DOI":"10.1001\/archinte.162.3.329"},{"key":"2021120819223396300_R30","doi-asserted-by":"crossref","unstructured":"Martin DL, MacDonald KL, White KE, et al. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med.\u20081990;323:1161\u20131167","DOI":"10.1056\/NEJM199010253231703"},{"key":"2021120819223396300_R31","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000"},{"key":"2021120819223396300_R32","doi-asserted-by":"crossref","unstructured":"Moritz ML, Ayus JC. Prevention of hospital-acquired hyponatremia: a case for using isotonic saline. Pediatrics.\u20082003;111:227\u2013230","DOI":"10.1542\/peds.111.2.227"},{"key":"2021120819223396300_R33","doi-asserted-by":"crossref","unstructured":"Moritz ML, Ayus JC. Hospital-acquired hyponatremia: why are there still deaths?Pediatrics.\u20082004;113:1395\u20131396","DOI":"10.1542\/peds.113.5.1395"},{"key":"2021120819223396300_R34","unstructured":"Talbot NB, Richie RR, Crawford JD. Maintenance therapy with multiple electrolyte solution. In: Metabolic Homeostasis: A Syllabus for Those Concerned With the Care of Patients. Boston, MA: Harvard University Press; 1959:84"},{"key":"2021120819223396300_R35","doi-asserted-by":"crossref","unstructured":"Brandt JR, Fouser LS, Watkins SL, et al. Escherichia coli O157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr.\u20081994;125:519\u2013526","DOI":"10.1016\/S0022-3476(94)70002-8"},{"key":"2021120819223396300_R36","doi-asserted-by":"crossref","unstructured":"Berman W Jr. The hemolytic-uremic syndrome: initial clinical presentation mimicking ulcerative colitis. J Pediatr.\u20081972;81:275\u2013278","DOI":"10.1016\/S0022-3476(72)80295-6"},{"key":"2021120819223396300_R37","doi-asserted-by":"crossref","unstructured":"Holliday MA, Segar WE, Friedman A. Reducing errors in fluid therapy management. Pediatrics.\u20082003;111:424\u2013425","DOI":"10.1542\/peds.111.2.424"},{"key":"2021120819223396300_R38","doi-asserted-by":"crossref","unstructured":"Bitzan M, Richardson S, Huang C, et al. Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro. Infect Immun.\u20081994;62:3337\u20133347","DOI":"10.1128\/iai.62.8.3337-3347.1994"},{"key":"2021120819223396300_R39","doi-asserted-by":"crossref","unstructured":"Jelacic S, Wobbe CL, Boster DR, et al. ABO and P1 blood group antigen expression and stx genotype and outcome of childhood Escherichia coli O157:H7 infections. J Infect Dis.\u20082002;185:214\u2013219","DOI":"10.1086\/338480"},{"key":"2021120819223396300_R40","doi-asserted-by":"crossref","unstructured":"Cornick NA, Jelacic S, Ciol MA, et al. Escherichia coli O157:H7 infections: discordance between filterable fecal Shiga toxin and disease outcome. J Infect Dis.\u20082002;186:57\u201363","DOI":"10.1086\/341295"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/6\/e673\/1027712\/zpe0060500e673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/6\/e673\/1027712\/zpe0060500e673.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T09:18:25Z","timestamp":1683105505000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/115\/6\/e673\/67459\/Relative-Nephroprotection-During-Escherichia-coli"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,6,1]]},"published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-2236","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,1]]}}}